2021
Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19 JACC State-of-the-Art Review
Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, Dreyfus I, Kakavand H, Ariannejad H, Gupta A, Madhavan MV, Van Tassell BW, Jimenez D, Monreal M, Vaduganathan M, Fanikos J, Dixon DL, Piazza G, Parikh SA, Bhatt DL, Lip GYH, Stone GW, Krumholz HM, Libby P, Goldhaber SZ, Bikdeli B. Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19 JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2021, 78: 1635-1654. PMID: 34649702, PMCID: PMC8504484, DOI: 10.1016/j.jacc.2021.08.021.Peer-Reviewed Original ResearchMeSH KeywordsAmidesCOVID-19COVID-19 Drug TreatmentEstersFatty Acids, Omega-3Fibric AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLipid Regulating AgentsNiacinRandomized Controlled Trials as TopicSulfhydryl CompoundsConceptsLipid-modulating agentsEndothelial activationLow high-density lipoprotein cholesterolCOVID-19High-density lipoprotein cholesterolLipid modulating agentsHigh triglyceride levelsMultiorgan manifestationsStatin trialsLipoprotein cholesterolSystemic inflammationTriglyceride levelsJACC StateWorse outcomesInflammatory responsePatient managementRCTsCoronavirus diseaseViral entrySystematic searchLipid raft disruptionTrialsPatientsRaft disruptionPreventionPrevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China
Lu Y, Zhang H, Lu J, Ding Q, Li X, Wang X, Sun D, Tan L, Mu L, Liu J, Feng F, Yang H, Zhao H, Schulz WL, Krumholz HM, Pan X, Li J, Huang C, Dong Z, Jiang B, Guo Z, Zhang Y, Sun J, Liu Y, Ren Z, Meng Y, Wang Z, Xi Y, Xing L, Tian Y, Liu J, Fu Y, Liu T, Sun W, Yan S, Jin L, Zheng Y, Wang J, Yan J, Xu X, Chen Y, Xing X, Zhang L, Zhong W, Fang X, Zhu L, Xu Y, Guo X, Xu C, Zhou G, Fan L, Qi M, Zhu S, Qi J, Li J, Yin L, Liu Q, Geng Q, Feng Y, Wang J, Wen H, Han X, Liu P, Ding X, Xu J, Deng Y, He J, Liu G, Jiang C, Zha S, Yang C, Bai G, Yu Y, Tashi Z, Qiu L, Hu Z, He H, Zhang J, Zhou M, Li X, Zhao J, Ma S, Ma Y, Huang Y, Zhang Y, Li F, Shen J. Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China. JAMA Network Open 2021, 4: e2127573. PMID: 34586366, PMCID: PMC8482054, DOI: 10.1001/jamanetworkopen.2021.27573.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge DistributionAgedCardiovascular DiseasesChinaCholesterol, LDLCross-Sectional StudiesDyslipidemiasFemaleHealth Services AccessibilityHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPrevalencePrimary Health CareConceptsAtherosclerotic cardiovascular diseaseLipid-lowering medicationsPrimary care institutionsPrevalence of dyslipidemiaControl of dyslipidemiaLipoprotein cholesterolCare institutionsControl rateFemale sexCardiovascular diseaseMAIN OUTCOMEHigh riskNonstatin lipid-lowering drugsHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolPrimary health care settingsMajor public health problemLipid lowering medicationsMillion Persons ProjectOverall control rateLDL-C levelsLipid-lowering drugsCross-sectional studyPublic health problemHealth care settingsAssociation between antecedent statin use and decreased mortality in hospitalized patients with COVID-19
Gupta A, Madhavan MV, Poterucha TJ, DeFilippis EM, Hennessey JA, Redfors B, Eckhardt C, Bikdeli B, Platt J, Nalbandian A, Elias P, Cummings MJ, Nouri SN, Lawlor M, Ranard LS, Li J, Boyle C, Givens R, Brodie D, Krumholz HM, Stone GW, Sethi SS, Burkhoff D, Uriel N, Schwartz A, Leon MB, Kirtane AJ, Wan EY, Parikh SA. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. Nature Communications 2021, 12: 1325. PMID: 33637713, PMCID: PMC7910606, DOI: 10.1038/s41467-021-21553-1.Peer-Reviewed Original ResearchMeSH KeywordsAgedCOVID-19COVID-19 Drug TreatmentFemaleHospital MortalityHospitalizationHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLogistic ModelsMaleMiddle AgedNew York CityPropensity ScoreRetrospective StudiesSARS-CoV-2ConceptsAcute respiratory distress syndromeStatin usePrimary endpointCOVID-19Multivariable logistic regression modelStudy periodLower inpatient mortalityPropensity-matched cohortRespiratory distress syndromeCoronavirus disease 2019Electronic medical recordsLogistic regression modelsPropensity-score matchingHospital mortalityHyperinflammatory stateOutpatient medicationsClinical characteristicsInpatient mortalityStatin usersThrombotic complicationsDistress syndromeHospitalized patientsMyocardial injuryMedical recordsRetrospective analysis
2020
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies
Bikdeli B, Talasaz AH, Rashidi F, Sharif-Kashani B, Farrokhpour M, Bakhshandeh H, Sezavar H, Dabbagh A, Beigmohammadi MT, Payandemehr P, Yadollahzadeh M, Riahi T, Khalili H, Jamalkhani S, Rezaeifar P, Abedini A, Lookzadeh S, Shahmirzaei S, Tahamtan O, Matin S, Amin A, Parhizgar SE, Jimenez D, Gupta A, Madhavan MV, Parikh SA, Monreal M, Hadavand N, Hajighasemi A, Maleki M, Sadeghian S, Mohebbi B, Piazza G, Kirtane AJ, Lip GYH, Krumholz HM, Goldhaber SZ, Sadeghipour P. Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. Thrombosis Research 2020, 196: 382-394. PMID: 32992075, PMCID: PMC7513771, DOI: 10.1016/j.thromres.2020.09.027.Peer-Reviewed Original ResearchConceptsStandard-dose prophylactic anticoagulationKey safety endpointIll patientsProphylactic anticoagulationVenous thromboembolismMajor bleedingSafety endpointCOVID-19Bleeding Academic Research Consortium definitionAcademic Research Consortium definitionsTimes upper normal limitAcute arterial thrombosisExuberant immune responseMacrovascular thrombotic eventsPrespecified secondary analysisCritically Ill PatientsKey secondary endpointVentilator-free daysExtracorporeal membrane oxygenationUpper normal limitNon-inferiority marginReverse transcription-polymerase chain reactionCoronavirus disease 2019Transcription-polymerase chain reactionAtorvastatin 20Secondary prevention of cardiovascular disease in China
Lu J, Zhang L, Lu Y, Su M, Li X, Liu J, Zhang H, Nasir K, Masoudi F, Krumholz H, Li J, Zheng X. Secondary prevention of cardiovascular disease in China. Heart 2020, 106: 1349-1356. PMID: 31980439, DOI: 10.1136/heartjnl-2019-315884.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAlcohol DrinkingCardiovascular DiseasesChinaFemaleHealthy LifestyleHeart Disease Risk FactorsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPlatelet Aggregation InhibitorsRisk AssessmentRisk Reduction BehaviorSecondary PreventionSex FactorsSmoking CessationTime FactorsTreatment OutcomeConceptsSecondary prevention drugsIschemic heart diseaseCardiovascular diseasePrevention drugsIschemic strokeSecondary preventionAntiplatelet drugsCardiac Events Million Persons ProjectHistory of IHDMillion Persons ProjectSecondary prevention therapiesPopulation subgroupsMultivariable mixed modelsPublic health programsCommunities of ChinaCurrent smokersCurrent useMedication usePrevention therapyMultivariable analysisChina PatientHeart diseaseCurrent drinkersHealth programsDrugs
2018
National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey
Salami JA, Warraich HJ, Valero‐Elizondo J, Spatz ES, Desai NR, Rana JS, Virani SS, Blankstein R, Khera A, Blaha MJ, Blumenthal RS, Katzen BT, Lloyd‐Jones D, Krumholz HM, Nasir K. National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey. Journal Of The American Heart Association 2018, 7: e007132. PMID: 29358195, PMCID: PMC5850149, DOI: 10.1161/jaha.117.007132.Peer-Reviewed Original ResearchAdultAgedAtherosclerosisDatabases, FactualDrug CostsDrug PrescriptionsDyslipidemiasFemaleHealth Care SurveysHealth ExpendituresHealthcare DisparitiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsLongitudinal StudiesMaleMedically UninsuredMiddle AgedPractice Patterns, Physicians'Racial GroupsRetrospective StudiesRisk FactorsSex FactorsSocioeconomic FactorsTime FactorsTreatment OutcomeUnited StatesRisks of Statins for Lower-Risk Individuals—Reply
Krumholz HM. Risks of Statins for Lower-Risk Individuals—Reply. JAMA 2018, 319: 310-310. PMID: 29340673, DOI: 10.1001/jama.2017.19174.Peer-Reviewed Original Research
2017
Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial
Arrieta A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial. JAMA Cardiology 2017, 2: 1369-1374. PMID: 29049467, PMCID: PMC5814995, DOI: 10.1001/jamacardio.2017.3655.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticholesteremic AgentsCardiovascular DiseasesCholesterol, LDLCost-Benefit AnalysisDecision Support TechniquesDrug Therapy, CombinationFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaInsuranceInsurance, HealthInsurance, Health, ReimbursementMaleMarkov ChainsMiddle AgedMyocardial InfarctionPCSK9 InhibitorsQuality-Adjusted Life YearsStrokeUnited StatesConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioCost-effectiveness ratioProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsCurrent pricesLife yearsPrivate payersAdditional quality-adjusted life yearPreliminary cost-effectiveness analysisCost-effectiveness standardsProbabilistic sensitivity analysesCost-effectiveness analysisPrivate payer perspectiveCost-effectiveness assessmentNegative returnsHealth system perspectiveSignificant discountUS dollarsDrug pricesPatent protectionPricesStatin treatment strategiesHealth insuranceTime horizonSubtilisin/kexin type 9 inhibitorsTreatment of Cholesterol in 2017
Krumholz HM. Treatment of Cholesterol in 2017. JAMA 2017, 318: 417-418. PMID: 28738130, DOI: 10.1001/jama.2017.6753.Peer-Reviewed Original ResearchCholesterol, LDLCoronary Artery DiseaseEvidence-Based MedicineHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaPractice Guidelines as TopicSecondary PreventionImplications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines A Cost-Effectiveness Analysis
Hong JC, Blankstein R, Shaw LJ, Padula WV, Arrieta A, Fialkow JA, Blumenthal RS, Blaha MJ, Krumholz HM, Nasir K. Implications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines A Cost-Effectiveness Analysis. JACC Cardiovascular Imaging 2017, 10: 938-952. PMID: 28797417, DOI: 10.1016/j.jcmg.2017.04.014.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAmerican Heart AssociationBayes TheoremClinical Decision-MakingComputer SimulationCoronary AngiographyCoronary Artery DiseaseCoronary VesselsCost-Benefit AnalysisDecision Support TechniquesDrug CostsFemaleGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedModels, EconomicMonte Carlo MethodMultivariate AnalysisPractice Guidelines as TopicPredictive Value of TestsQuality of LifeQuality-Adjusted Life YearsTime FactorsTreatment OutcomeUnited StatesVascular CalcificationConceptsCoronary artery calciumQuality-adjusted life yearsStatin therapyArtery calciumLong-term statin therapyAtherosclerotic cardiovascular disease eventsCholesterol management guidelinesIncremental cost-effectiveness ratioCardiovascular disease eventsAtherosclerotic cardiovascular diseaseCost-effectiveness ratioCost-effectiveness analysisStatin candidatesCholesterol managementCardiovascular diseaseTreatment decisionsAmerican CollegeDisease eventsLifetime horizonLife yearsAmerican HeartSocietal perspectiveManagement guidelinesStatinsPatientsHospital Performance on Percutaneous Coronary Intervention Process and Outcomes Measures
Chui PW, Parzynski CS, Nallamothu BK, Masoudi FA, Krumholz HM, Curtis JP. Hospital Performance on Percutaneous Coronary Intervention Process and Outcomes Measures. Journal Of The American Heart Association 2017, 6: e004276. PMID: 28446493, PMCID: PMC5524055, DOI: 10.1161/jaha.116.004276.Peer-Reviewed Original ResearchMeSH KeywordsCardiac RehabilitationCoronary DiseaseCross-Sectional StudiesHealthcare DisparitiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMedicarePatient DischargePatient ReadmissionPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsProcess Assessment, Health CareQuality ImprovementQuality Indicators, Health CareReferral and ConsultationRegistriesRisk FactorsTime FactorsTime-to-TreatmentTreatment OutcomeUnited StatesConceptsProcess measuresReadmission ratesOutcome measuresNational Cardiovascular Data Registry CathPCI RegistryHospital performancePercutaneous coronary interventionSpecific process measuresRisk-standardized mortalityPCI patientsCathPCI RegistryCoronary interventionHospital variationOutcome ratesHospital qualityPhysician ConsortiumMortalitySmall percentageWeak correlationAssociationIntervention processPatientsPatient–Provider Communication and Health Outcomes Among Individuals With Atherosclerotic Cardiovascular Disease in the United States
Okunrintemi V, Spatz ES, Di Capua P, Salami JA, Valero-Elizondo J, Warraich H, Virani SS, Blaha MJ, Blankstein R, Butt AA, Borden WB, Dharmarajan K, Ting H, Krumholz HM, Nasir K. Patient–Provider Communication and Health Outcomes Among Individuals With Atherosclerotic Cardiovascular Disease in the United States. Circulation Cardiovascular Quality And Outcomes 2017, 10: e003635. PMID: 28373270, DOI: 10.1161/circoutcomes.117.003635.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAspirinAtherosclerosisCommunicationEmergency Service, HospitalFemaleHealth Care CostsHealth Care SurveysHealth ExpendituresHealth StatusHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLength of StayMaleMental HealthMiddle AgedOdds RatioPatient Reported Outcome MeasuresPatient-Centered CarePhysician-Patient RelationsPlatelet Aggregation InhibitorsQuality Indicators, Health CareRisk FactorsUnited StatesYoung AdultConceptsAtherosclerotic cardiovascular diseasePatient-provider communicationHealthcare resource utilizationPatient-reported outcomesCardiovascular diseaseHealth Plans SurveyMedical Expenditure Panel Survey cohortHigher annual healthcare expendituresRepresentative US adult populationHealthcare expendituresAtherosclerotic cardiovascular disease (ASCVD) patientsConsumer AssessmentEmergency room visitsEvidence-based therapiesAnnual healthcare expendituresCardiovascular disease patientsUS adult populationPlans SurveyMental health statusPatient-centered careOutcomes of interestASA useHospital stayRoom visitsPoor outcome
2016
Access to Evidence-Based Statins in Low-Cost Generic Drug Programs
Jackevicius CA, Choi K, Krumholz HM. Access to Evidence-Based Statins in Low-Cost Generic Drug Programs. Circulation Cardiovascular Quality And Outcomes 2016, 9: 785-787. PMID: 27803089, DOI: 10.1161/circoutcomes.116.002985.Peer-Reviewed Original ResearchDrug CostsDrugs, GenericEvidence-Based MedicineHealth Services AccessibilityHumansHydroxymethylglutaryl-CoA Reductase InhibitorsPrescription DrugsSex differences in lipid profiles and treatment utilization among young adults with acute myocardial infarction: Results from the VIRGO study
Lu Y, Zhou S, Dreyer RP, Caulfield M, Spatz ES, Geda M, Lorenze NP, Herbert P, D'Onofrio G, Jackson EA, Lichtman JH, Bueno H, Spertus JA, Krumholz HM. Sex differences in lipid profiles and treatment utilization among young adults with acute myocardial infarction: Results from the VIRGO study. American Heart Journal 2016, 183: 74-84. PMID: 27979045, PMCID: PMC5459396, DOI: 10.1016/j.ahj.2016.09.012.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnticholesteremic AgentsCholesterol, HDLCholesterol, LDLFemaleFollow-Up StudiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLinear ModelsLipidsMaleMiddle AgedMyocardial InfarctionSex FactorsYoung AdultConceptsAcute myocardial infarctionLipid profileYoung womenLipoprotein cholesterolLipoprotein profileMyocardial infarctionTreatment utilizationLow-density lipoprotein cholesterolHigh-density lipoprotein cholesterolLow HDL cholesterol levelsYoung adultsHigh-intensity doseMajor lipid abnormalitiesSex differencesAdverse lipid profileFavorable lipoprotein profileHDL cholesterol ratioLower total cholesterolHDL cholesterol levelsHigher HDL cholesterolImportant risk factorHigher mortality riskMultivariate regression analysisVIRGO StudyCardiovascular outcomesStatins evidence: when answers also raise questions
Krumholz HM. Statins evidence: when answers also raise questions. The BMJ 2016, 354: i4963. PMID: 27628589, DOI: 10.1136/bmj.i4963.Peer-Reviewed Original ResearchCardiovascular DiseasesClinical Trials as TopicEvidence-Based MedicineHumansHydroxymethylglutaryl-CoA Reductase InhibitorsObservational Studies as TopicRandomized Controlled Trials as TopicRisk FactorsNational Assessment of Statin Therapy in Patients Hospitalized with Acute Myocardial Infarction: Insight from China PEACE-Retrospective AMI Study, 2001, 2006, 2011
Zhang L, Li J, Li X, Nasir K, Zhang H, Wu Y, Hu S, Wang Q, Downing NS, Desai NR, Masoudi FA, Spertus JA, Krumholz HM, Jiang L, . National Assessment of Statin Therapy in Patients Hospitalized with Acute Myocardial Infarction: Insight from China PEACE-Retrospective AMI Study, 2001, 2006, 2011. PLOS ONE 2016, 11: e0150806. PMID: 27058862, PMCID: PMC4825974, DOI: 10.1371/journal.pone.0150806.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedChinaFemaleFollow-Up StudiesHospitalizationHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedMyocardial InfarctionRetrospective StudiesTime FactorsTreatment OutcomeConceptsAcute myocardial infarctionIntensive statin therapyLow-density lipoprotein cholesterolAcute myocardial infarction patientsStatin therapyMyocardial infarction patientsMyocardial infarctionStatin useLipoprotein cholesterolInfarction patientsHalf of patientsLong-term mortalityUse of statinsHospitalized patientsIntensive therapyChinese patientsCardiovascular diseaseEffective treatmentPatientsInfarctionStatinsTherapyChinese hospitalsTreatment intensityCholesterolReply Coronary Artery Calcification Testing: A Platonic Certainty
Nasir K, Krumholz HM. Reply Coronary Artery Calcification Testing: A Platonic Certainty. Journal Of The American College Of Cardiology 2016, 67: 1126-1127. PMID: 26940937, DOI: 10.1016/j.jacc.2015.12.027.Peer-Reviewed Original ResearchCalciumCoronary Artery DiseaseCoronary VesselsEthnicityFemaleGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleRadiographyRisk Assessment
2015
2015 ACC/AHA Focused Update of Secondary Prevention Lipid Performance Measures A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures
Drozda JP, Ferguson TB, Jneid H, Krumholz HM, Nallamothu BK, Olin JW, Ting HH. 2015 ACC/AHA Focused Update of Secondary Prevention Lipid Performance Measures A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Journal Of The American College Of Cardiology 2015, 67: 558-587. PMID: 26698405, DOI: 10.1016/j.jacc.2015.02.003.Peer-Reviewed Original ResearchMeSH KeywordsAdvisory CommitteesAmerican Heart AssociationCardiologyCardiovascular DiseasesHealth Services Needs and DemandHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipidemiasNeeds AssessmentPatient Care PlanningQuality ImprovementSecondary PreventionUnited States2015 ACC/AHA Focused Update of Secondary Prevention Lipid Performance Measures
Drozda J, Ferguson T, Jneid H, Krumholz H, Nallamothu B, Olin J, Ting H, Heidenreich P, Albert N, Chan P, Curtis L, Ferguson T, Fonarow G, Ho P, O'Brien S, Russo A, Thomas R, Ting H, Varosy P. 2015 ACC/AHA Focused Update of Secondary Prevention Lipid Performance Measures. Circulation Cardiovascular Quality And Outcomes 2015, 9: 68-95. PMID: 26666514, DOI: 10.1161/hcq.0000000000000014.Peer-Reviewed Original ResearchAdvisory CommitteesAmerican Heart AssociationCardiologyCardiovascular DiseasesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipidemiasMedication AdherencePractice Guidelines as TopicSecondary PreventionUnited StatesImplications of Coronary Artery Calcium Testing Among Statin Candidates According to American College of Cardiology/American Heart Association Cholesterol Management Guidelines MESA (Multi-Ethnic Study of Atherosclerosis)
Nasir K, Bittencourt MS, Blaha MJ, Blankstein R, Agatson AS, Rivera JJ, Miedema MD, Sibley CT, Shaw LJ, Blumenthal RS, Budoff MJ, Krumholz HM. Implications of Coronary Artery Calcium Testing Among Statin Candidates According to American College of Cardiology/American Heart Association Cholesterol Management Guidelines MESA (Multi-Ethnic Study of Atherosclerosis). Journal Of The American College Of Cardiology 2015, 66: 1657-1668. PMID: 26449135, DOI: 10.1016/j.jacc.2015.07.066.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAmerican Heart AssociationAtherosclerosisCalciumCoronary AngiographyCoronary Artery DiseaseCoronary VesselsEthnicityFemaleFollow-Up StudiesGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedProspective StudiesRisk AssessmentRisk FactorsUnited StatesConceptsCoronary artery calciumASCVD event ratesYears of ageStatin therapyAmerican CollegeAbsence of CACHard coronary heart disease eventsNew ACC/AHA guidelinesCoronary Artery Calcium TestingACC/AHA guidelinesAtherosclerotic cardiovascular disease riskCoronary heart disease eventsLow-density lipoprotein levelsEvent ratesCholesterol management guidelinesHigh-intensity statinsHeart disease eventsLipid-lowering medicationsModerate-intensity statinsCardiovascular disease riskLow-density lipoproteinStatin candidatesASCVD riskAHA guidelinesArtery calcium